Breaking News Instant updates and real-time market news.

NVCN

Neovasc

$3.72

0.17 (4.79%)

07:18
10/22/19
10/22
07:18
10/22/19
07:18

Neovasc announces multiple presentations featuring Neovasc Reducer

Neovasc announced that the Neovasc Reducer was featured in multiple presentations during the symposium "A Proven Evidence-based therapy when Angina Persists", held this month at the National Congress of the Italian Society of Interventional Cardiology in Milan, Italy. The highlights showed that 50% of the patients improved by 2 CCS Classes or more while 83% of patients improved by 1 CCS Class or more. Seventeen percent did not respond to the therapy. Additionally, the average CCS score decreased from 3.2 to 1.7. In selected presentations: Prof Shmuel Banai, Director, Division of Cardiology Tel-Aviv Medical Center, and Neovasc Medical Director, presented the history and rationale of coronary sinus narrowing for the treatment of angina. In 1948, American Cardiac Surgeon, Claude Schaffer Beck, developed an effective treatment for patients with disabling angina by creating a surgical narrowing of the coronary sinus. Between the years 1948 to 1964 Dr. Beck successfully used this procedure on more than 1,000 patients with coronary heart disease. In 1952, Dr. Beck became the first to receive the title of professor of cardiovascular surgery in the United States. More recently, Neovasc developed non-surgical methods to narrow the coronary sinus in Europe and Canada. These methods proved effective, enhancing blood supply to the ischemic heart, increasing quality of life and protecting the heart while reducing infarct size. Pr. Sergio Berti, Fondazione Toscana G. Monasterio, based on recent survey data of clinical cardiologists in the Milan area, reinforced that many patients suffer from angina despite optimal therapy. The clinical cardiologists polled estimate that as many as 12% of their angina patients are refractory to currently available therapies. On average, these physicians each had 20 such patients, of which approximately 50% were not satisfied with their current therapy. Physicians confirmed they would likely have sent these patients for a definitive interventional treatment, if they were aware of such a therapy. The conclusion of the survey was that there are still many patients with refractory angina, who are not satisfied with their quality of life or their current therapy, and who could potentially benefit from the Reducer. These leading cardiologists reinforced that the suffering of patients has a significant impact on their everyday life. As a measure of that, these patients on average return for a consultation on a monthly basis. Dr. Francesco Giannini, GVM Care & Research Maria Cecilia Hospital - Cotignola, reviewed the technical and procedural aspect of the Reducer Therapy. During his presentation, Dr. Giannini reinforced the strong safety profile of the procedure. On behalf of the investigators, Dr. Gianpiero D'Amico, University of Padua, presented the Italian Society of Interventional Cardiology Multi-Center study on the "Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina." One hundred eighty three patients suffering from severe refractory angina were treated with coronary sinus narrowing by Reducer implantation in 16 medical centers across Italy. Presented data demonstrated a 98% technical success rate. Efficacy data at median follow-up of 564 days showed significant improvements in angina severity with minimal rates of complications. Results, based on the Canadian Cardiovascular Society Class, showed that 50% of the patients improved by 2 CCS Classes or more, 83% of patients improved by 1 CCS Class or more and 17% did not respond to the therapy. The average CCS score decreased from 3.2 to 1.7. Quality of life as assessed by the Seattle Angina Questionnaire also improved significantly across all 5 domains. Data comparing the CCS Class improvement results of the Italian registry to seven other previously published Reducer studies demonstrated consistent results across all studies. Finally, the current President of GISE, Pr. Giuseppe Tarantini, University of Padua, reinforced the importance of the new European Society of Cardiology guidelines for the Reducer Therapy and the importance of this therapy for patients who currently have few treatment options

NVCN Neovasc
$3.72

0.17 (4.79%)

03/22/19
ADAM
03/22/19
NO CHANGE
Target $1.1
ADAM
Buy
Neovasc court win in Germany removes overhang, says Canaccord
Canaccord analyst Jason Mills said the ruling yesterday from a German court in dismissing the claim to co-inventorship of the Tiara device made by Edwards Lifesciences' (EW) CardiAQ removes a litigation overhang for Neovasc (NVCN). Mills continues to view Neovasc as an "attractive, albeit admittedly risky," play on the Transcatheter Mitral Valve Repair sector and keeps a Buy rating and $1.10 price target on the shares.

TODAY'S FREE FLY STORIES

04:00
11/13/19
11/13
04:00
11/13/19
04:00
General news
FX Action: USD-CAD has posted a fresh one-month peak »

FX Action: USD-CAD has…

02:50
11/13/19
11/13
02:50
11/13/19
02:50
General news
FX Update: The New Zealand dollar surged by over 1% »

FX Update: The New…

01:55
11/13/19
11/13
01:55
11/13/19
01:55
General news
Asian Market Update: »

Asian Market Update:…

01:55
11/13/19
11/13
01:55
11/13/19
01:55
General news
U.S. CPI preview: analysts're forecasting a »

U.S. CPI preview:…

01:30
11/13/19
11/13
01:30
11/13/19
01:30
General news
Fed's Kashkari now a little more optimistic on the U.S. economy »

Fed's Kashkari now a…

WSM

Williams-Sonoma

$70.48

-0.88 (-1.23%)

21:33
11/12/19
11/12
21:33
11/12/19
21:33
Initiation
Williams-Sonoma initiated at Barclays »

Williams-Sonoma initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$84.57

1.28 (1.54%)

21:31
11/12/19
11/12
21:31
11/12/19
21:31
Initiation
Wayfair initiated at Barclays »

Wayfair initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

VFC

VF Corp.

$84.69

-1.7 (-1.97%)

21:28
11/12/19
11/12
21:28
11/12/19
21:28
Initiation
VF Corp. initiated at Barclays »

VF Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URBN

Urban Outfitters

$30.85

0.295 (0.97%)

21:25
11/12/19
11/12
21:25
11/12/19
21:25
Initiation
Urban Outfitters initiated at Barclays »

Urban Outfitters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

UAA

Under Armour

$17.29

-0.295 (-1.68%)

21:23
11/12/19
11/12
21:23
11/12/19
21:23
Initiation
Under Armour initiated at Barclays »

Under Armour initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ULTA

Ulta Beauty

$244.06

2.19 (0.91%)

21:19
11/12/19
11/12
21:19
11/12/19
21:19
Initiation
Ulta Beauty initiated at Barclays »

Ulta Beauty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

TJX

TJX

$58.40

-0.14 (-0.24%)

21:15
11/12/19
11/12
21:15
11/12/19
21:15
Initiation
TJX initiated at Barclays »

TJX initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

TPR

Tapestry

$26.38

-0.295 (-1.11%)

21:12
11/12/19
11/12
21:12
11/12/19
21:12
Initiation
Tapestry initiated at Barclays »

Tapestry initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

AFL

Aflac

$53.97

-0.04 (-0.07%)

21:02
11/12/19
11/12
21:02
11/12/19
21:02
Hot Stocks
Aflac names Frederick Crawford new COO »

Aflac announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROST

Ross Stores

$110.97

-1.16 (-1.03%)

21:00
11/12/19
11/12
21:00
11/12/19
21:00
Initiation
Ross Stores initiated at Barclays »

Ross Stores initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

RL

Ralph Lauren

$111.44

-2.58 (-2.26%)

20:57
11/12/19
11/12
20:57
11/12/19
20:57
Initiation
Ralph Lauren initiated at Barclays »

Ralph Lauren initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$174.48

-0.18 (-0.10%)

20:56
11/12/19
11/12
20:56
11/12/19
20:56
Initiation
RH initiated at Barclays »

RH initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVH

PVH Corp.

$96.91

0.14 (0.14%)

20:53
11/12/19
11/12
20:53
11/12/19
20:53
Initiation
PVH Corp. initiated at Barclays »

PVH Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

JWN

Nordstrom

$36.90

-0.52 (-1.39%)

20:51
11/12/19
11/12
20:51
11/12/19
20:51
Initiation
Nordstrom initiated at Barclays »

Nordstrom initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

NKE

Nike

$89.51

-0.52 (-0.58%)

20:46
11/12/19
11/12
20:46
11/12/19
20:46
Initiation
Nike initiated at Barclays »

Nike initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EYE

National Vision

$27.03

0.24 (0.90%)

20:43
11/12/19
11/12
20:43
11/12/19
20:43
Initiation
National Vision initiated at Barclays »

National Vision initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$17.53

0.02 (0.11%)

20:40
11/12/19
11/12
20:40
11/12/19
20:40
Initiation
L Brands initiated at Barclays »

L Brands initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

BABA

Alibaba

$186.97

0.26 (0.14%)

20:25
11/12/19
11/12
20:25
11/12/19
20:25
Periodicals
Alibaba gets approval to sell shares in Hong Kong, SCMP reports »

Alibaba has received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

ENR

Energizer

$42.01

-1.1 (-2.55%)

, SPB

Spectrum Brands

$51.19

-0.76 (-1.46%)

20:25
11/12/19
11/12
20:25
11/12/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

ENR

Energizer

$42.01

-1.1 (-2.55%)

SPB

Spectrum Brands

$51.19

-0.76 (-1.46%)

SSYS

Stratasys

$20.74

0.04 (0.19%)

FVRR

Fiverr

$21.56

-0.47 (-2.13%)

MTOR

Meritor

$23.44

-0.25 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 21

    Nov

  • 09

    Dec

  • 12

    Dec

DDOG

Datadog

$34.40

0.89 (2.66%)

20:02
11/12/19
11/12
20:02
11/12/19
20:02
Hot Stocks
Datadog establishes Japanese subsidiary »

Datadog announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 19

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.